BR9510067A - Peptídio capaz de interagir com o domínio sh3 da proteína gap anticorpo ou fragmento de anticorpo dirigido contra um polipeptídeo sequência nucleotídica codificando para um polipeptídio ácido nucléico anti-sentido capaz de inibir ao menos parcialmente a produção de polipeptídeos sua utilização composição farmacêutica e utilização de um anticorpo ou fragmento de anticorpo - Google Patents

Peptídio capaz de interagir com o domínio sh3 da proteína gap anticorpo ou fragmento de anticorpo dirigido contra um polipeptídeo sequência nucleotídica codificando para um polipeptídio ácido nucléico anti-sentido capaz de inibir ao menos parcialmente a produção de polipeptídeos sua utilização composição farmacêutica e utilização de um anticorpo ou fragmento de anticorpo

Info

Publication number
BR9510067A
BR9510067A BR9510067A BR9510067A BR9510067A BR 9510067 A BR9510067 A BR 9510067A BR 9510067 A BR9510067 A BR 9510067A BR 9510067 A BR9510067 A BR 9510067A BR 9510067 A BR9510067 A BR 9510067A
Authority
BR
Brazil
Prior art keywords
antibody
antibody fragment
interacting
domain
nucleic acid
Prior art date
Application number
BR9510067A
Other languages
English (en)
Inventor
Marc Duchesne
Fabienne Parker
Didier Faucher
Fabien Schweighoffer
Bruno Tocque
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9413955A external-priority patent/FR2727116B1/fr
Priority claimed from FR9505753A external-priority patent/FR2734266B1/fr
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of BR9510067A publication Critical patent/BR9510067A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR9510067A 1994-11-22 1995-11-22 Peptídio capaz de interagir com o domínio sh3 da proteína gap anticorpo ou fragmento de anticorpo dirigido contra um polipeptídeo sequência nucleotídica codificando para um polipeptídio ácido nucléico anti-sentido capaz de inibir ao menos parcialmente a produção de polipeptídeos sua utilização composição farmacêutica e utilização de um anticorpo ou fragmento de anticorpo BR9510067A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9413955A FR2727116B1 (fr) 1994-11-22 1994-11-22 Peptides capables de se lier au domaine sh3 de la proteine gap, sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation
FR9505753A FR2734266B1 (fr) 1995-05-16 1995-05-16 Peptides capables de se lier au domaine sh3 de la proteine gap sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation
PCT/FR1995/001539 WO1996016169A1 (fr) 1994-11-22 1995-11-22 Peptides capables de se lier au domaine sh3 de la proteine gap, sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation

Publications (1)

Publication Number Publication Date
BR9510067A true BR9510067A (pt) 1997-12-30

Family

ID=26231549

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9510067A BR9510067A (pt) 1994-11-22 1995-11-22 Peptídio capaz de interagir com o domínio sh3 da proteína gap anticorpo ou fragmento de anticorpo dirigido contra um polipeptídeo sequência nucleotídica codificando para um polipeptídio ácido nucléico anti-sentido capaz de inibir ao menos parcialmente a produção de polipeptídeos sua utilização composição farmacêutica e utilização de um anticorpo ou fragmento de anticorpo

Country Status (18)

Country Link
US (1) US5886150A (pt)
EP (1) EP0793721B1 (pt)
JP (2) JPH10509044A (pt)
AT (1) ATE305037T1 (pt)
AU (1) AU713937B2 (pt)
BR (1) BR9510067A (pt)
CA (1) CA2204438A1 (pt)
CZ (1) CZ292538B6 (pt)
DE (1) DE69534471T2 (pt)
DK (1) DK0793721T3 (pt)
ES (1) ES2248800T3 (pt)
FI (1) FI972170A0 (pt)
HU (1) HU221410B1 (pt)
IL (1) IL116026A (pt)
MX (1) MX9703364A (pt)
NO (1) NO972313D0 (pt)
SK (1) SK287034B6 (pt)
WO (1) WO1996016169A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780062B1 (fr) * 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
HU228582B1 (en) * 1998-10-23 2013-04-29 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE60138321D1 (de) * 2000-06-16 2009-05-20 Rudel Thomas Verfahren zur Identifizierung während der Apoptose modifizierter Proteine
JP2004532981A (ja) * 2001-04-10 2004-10-28 チルドレンズ メディカル センター コーポレーション タンパク質−タンパク質相互作用の解析および標識の方法
JPWO2003006060A1 (ja) * 2001-07-09 2004-10-28 協和醗酵工業株式会社 Ｓｈ３ドメイン結合阻害剤
US20050069999A1 (en) * 2001-07-09 2005-03-31 Sharma Sreenath V Sh3 domain binding inhibitors
AUPR721101A0 (en) * 2001-08-23 2001-09-13 University Of Queensland, The Nucleic acid and polypeptide linked to breast cancer
US8143380B2 (en) * 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
JP5017116B2 (ja) * 2004-09-24 2012-09-05 アムジエン・インコーポレーテツド 修飾Ｆｃ分子
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US11237168B2 (en) * 2019-06-26 2022-02-01 St. Jude Children's Research Hospital Method for identifying modulators of G3BP activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA894726B (en) * 1988-06-27 1990-03-28 Akzo Nv Coccidiosis vaccine
ATE181332T1 (de) * 1989-08-21 1999-07-15 Chiron Corp Vom gtpase-aktivierenden protein (gap) abgeleitete peptide sowie deren diagnostische und therapeutische verwendung
CA2057675A1 (en) * 1990-12-24 1992-06-25 Michael D. Schaber Peptide inhibitors of ras-gap interaction
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
CA2153486A1 (en) * 1993-01-15 1994-07-21 Masato Nakafuku Ras associated gap proteins

Also Published As

Publication number Publication date
AU713937B2 (en) 1999-12-16
ATE305037T1 (de) 2005-10-15
FI972170A (fi) 1997-05-21
HU221410B1 (en) 2002-09-28
DE69534471T2 (de) 2006-06-22
JPH10509044A (ja) 1998-09-08
CZ292538B6 (cs) 2003-10-15
SK62997A3 (en) 1998-02-04
DE69534471D1 (de) 2006-02-02
EP0793721B1 (fr) 2005-09-21
JP2006122049A (ja) 2006-05-18
US5886150A (en) 1999-03-23
NO972313L (no) 1997-05-21
AU4263696A (en) 1996-06-17
SK287034B6 (sk) 2009-10-07
MX9703364A (es) 1997-08-30
HUT77029A (hu) 1998-03-02
FI972170A0 (fi) 1997-05-21
CA2204438A1 (fr) 1996-05-30
IL116026A (en) 2005-08-31
EP0793721A1 (fr) 1997-09-10
IL116026A0 (en) 1996-01-31
WO1996016169A1 (fr) 1996-05-30
CZ154597A3 (en) 1997-10-15
DK0793721T3 (da) 2006-01-30
ES2248800T3 (es) 2006-03-16
NO972313D0 (no) 1997-05-21

Similar Documents

Publication Publication Date Title
BR9510067A (pt) Peptídio capaz de interagir com o domínio sh3 da proteína gap anticorpo ou fragmento de anticorpo dirigido contra um polipeptídeo sequência nucleotídica codificando para um polipeptídio ácido nucléico anti-sentido capaz de inibir ao menos parcialmente a produção de polipeptídeos sua utilização composição farmacêutica e utilização de um anticorpo ou fragmento de anticorpo
TR200001709T2 (tr) Yeni neisseria meningitids yüzey proteini
LU93259I2 (fr) LETIFEND (Protein Q)
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
AU5628394A (en) Granulocyte chemotactic protein
AU5508396A (en) Pcna binding substance
HUP0004605A1 (hu) Presenilinek és a béta-amiloid peptid vagy prekurzora közötti kölcsönhatás gátlására képes peptidek
ATE215123T1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
WO2001036626A3 (en) Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds
IT1275909B1 (it) Frammento di dna codificante d-amminoacido ossidasi
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
EE05139B1 (et) Peptiid, seda kodeeriv geen, reagent ja reaktiivikomplekt riketsioosi tuvastamiseks ning peptiidi sisaldav vaktsiin
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
AU1993201A (en) Nucleic acid sequences of hyperplasia and tumours of the thyroid
NO973876D0 (no) Human-DNase I-varianter
HUP0004739A1 (hu) Presenilinekkel kölcsönhatásra képes fehérjéket kódoló nukleinsavak
WO2002031127A3 (en) Cloning and recombinant expression of mammalian group xii secreted phospholipase a¿2?
WO2003044159A9 (en) Zinc finger proteins, polynucleotides encoding same and antibodies thereto
BG101847A (en) Human dnase i variants

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: AVENTIS PHARMA S.A. (FR)

Free format text: ALTERADO DE: RHONE-POULENC RORER S.A.